equipulmin vet. 25 mikrogram/ml syrup
cp-pharma handelsgesellschaft mbh - clenbuterolhydrochlorid - syrup - 25 mikrogram/ml - hest
equisedan 10 mg/ml injektionsvæske, opløsning
vetcare oy - detomidinhydrochlorid - injektionsvæske, opløsning - 10 mg/ml - hest
ruvax vet. 25 ie/ml injektionsvæske, suspension
boehringer ingelheim animal health nordics a/s - erysipelothrix rhusiopathiae serotype 2 (inaktiveret) - injektionsvæske, suspension - 25 ie/ml - svin
dilaterol vet. 25 mikrogram/ml syrup
le vet beheer b.v. - clenbuterolhydrochlorid - syrup - 25 mikrogram/ml - hest
dalmarelin 25 mikg/ml injektionsvæske, opløsning
fatro s.p.a. - lecirelinacetat - injektionsvæske, opløsning - 25 mikg/ml
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. se afsnit 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
renvela
sanofi b.v. - sevelamercarbonat - hyperphosphatemia; renal dialysis - alle andre terapeutiske produkter - renvela er indiceret til bekæmpelse af hyperphosphatæmi hos voksne patienter, der modtager hæmodialyse eller peritonealdialyse. renvela er også indiceret til kontrol af hyperphosphataemia i voksne patienter med kronisk nyresygdom, der ikke er i dialyse med serum fosfor ≥ 1. 78 mmol/l. renvela bør anvendes i forbindelse med flere terapeutiske tilgang, der kan omfatte calcium supplement, 1,25-dihydroxy vitamin d3 eller en af dets analoger at styre udviklingen af renal knoglesygdom.
sevelamer carbonate winthrop (previously sevelamer carbonate zentiva)
sanofi b.v. - sevelamercarbonat - hyperphosphatemia; renal dialysis - alle andre terapeutiske produkter - sevelamer karbonat winthrop er indiceret til kontrol af hyperphosphataemia hos voksne patienter, der får hæmodialyse eller peritoneal dialyse. sevelamer karbonat winthrop er også indiceret til kontrol af hyperphosphataemia i voksne patienter med kronisk nyresygdom, der ikke er i dialyse med serum fosfor > 1. 78 mmol / l. sevelamer karbonat winthrop bør anvendes i forbindelse med flere terapeutiske tilgang, der kan omfatte calcium supplement, 1,25-dihydroxy vitamin d3 eller en af dets analoger at styre udviklingen af renal knoglesygdom.
renagel
sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - alle andre terapeutiske produkter - renagel is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.
octagam 50 mg/ml infusionsvæske, opløsning
octapharma ab - normalt immunglobulin, humant - infusionsvæske, opløsning - 50 mg/ml